Replimune Group, Inc. — Form 8-K Summary
Reporting date: August 7, 2019; filed August 8, 2019. The filing reports material financing arrangements and does not provide operating or period-end financial results.
Business Context and Reporting Period
Replimune Group, Inc. is a Delaware biotechnology company headquartered in Woburn, Massachusetts. Its common stock trades on Nasdaq under the symbol REPL. The company identified itself as an emerging growth company.
Material Financing Arrangements
- At-the-market equity program: Replimune entered into a sales agreement with SVB Leerink LLC allowing it, at its option, to sell up to $75.0 million of common stock from time to time through an at-the-market or negotiated offering.
- The equity sales are subject to the effectiveness of a Form S-3 registration statement covering up to $250.0 million of various securities. Replimune will pay the agent a 3.0% commission on gross proceeds from shares sold. The company has not committed to issue any shares under the program.
- Term loan facility: Hercules Capital agreed to make available a secured term loan facility of up to $30.0 million. The filing states that Replimune borrowed $10.0 million in a single advance.
- The loan bears interest at the greater of the Wall Street Journal prime rate plus 2.75% or 8.75%. Monthly interest is payable until March 1, 2022, after which equal monthly principal and interest installments are due through repayment.
- The loan matures on August 1, 2023 and is secured by substantially all company assets, excluding intellectual property and subject to specified exclusions. The company paid or agreed to pay a $225,000 facility charge and an additional fee equal to 4.95% of advances.
Material Changes, Outlook, and Risks
- The filing creates potential access to substantial additional equity capital but could result in dilution if shares are sold.
- The term loan increases secured debt obligations and includes restrictions on additional debt, liens, acquisitions, loans, dividends, dissolutions, leases, and asset sales.
- Prepayment charges apply to the term loan: 3.0% during the first 12 months, 2.0% from months 13 through 24, and 1.0% thereafter.
- Customary events of default include nonpayment, bankruptcy, covenant breaches, inaccurate representations, change of control, judgments, and material adverse effects.
- The filing does not provide revenue, net income, margins, cash flow, cash balance, liquidity runway, or management operating guidance.
Important Facts to Verify
- Whether any shares have actually been sold under the $75.0 million ATM program and the resulting dilution and net proceeds.
- Whether the Form S-3 registration statement became effective and the remaining securities capacity available under it.
- The outstanding principal balance, interest rate, repayment schedule, and financial covenants under the Hercules facility.
- The filing contains a date inconsistency: the narrative refers to the loan agreement and closing date as August 7, 2018, while the exhibit description identifies the Loan and Security Agreement as dated August 7, 2019. The definitive agreement should be reviewed to confirm the applicable date and whether this reflects an amendment, refinancing, or drafting error.